Stephen P. MacMillan
total guidance the as Mike, finished within you, overall both of quarter fourth fiscal per ranges. for of discuss and solid share XXXX. and results quarter earnings Thank good was $X.XX financial afternoon, to everyone. $XXX.X pleased our Hologic's of It a million We're revenue
due MonaLisa laser Vitalia to marketing expected lower our in letter and our legacy probes. on sales TempSure our continued offset Touch we As September, FDA announced of and of products Cynosure the in than decision handpieces suspend to strength businesses
a quarter, accelerated a consecutive ago. in for trend year. just Molecular solidly Our growth our Health and continuing from completed performed Surgical growth. emerged domestic further the year course royalties returned acquisition Health fourth Breast International the our strengthen quarter. improved expand the the increased tuck-in will largest that U.S. excluding non-recurring fifth we Growth of And over a Breast well to that quarter-end, in businesses franchise. business sales after and
details, Before company comment whole end let of and on we're these fiscal step the marking discuss since as me back our a year. we the
strong Bioptics In a improved Aesthetics, As improved more dramatically our infrastructure of sustainable sales In domestic and new competitive our execution. businesses capabilities sheet, across results Faxitron new products, than it debt development don't major in eliminated over I Focal year steadily. we is the course by of the growth look capabilities. revamped that balance convertible a back And Therapeutics. our company placed there and improve from helped Medical leadership, we numbers and doubt our much Breast In today are solidified Diagnostics, Panthers, In we launched we XXXX more growth largest no more stronger. that products ago healthier of XXXX, and Health, each a tests, and our with new driven Surgical, our customers. relationships is new efforts, all the quarterly commercial a show acquisitions solid resulting for business with as we Internationally, although we finally, the enhanced and yet. force of built
ahead. four have and more expect completed successfully We now deals tuck-in
XXXX early leadership we momentum. since we So year, improved made overall, in progress with enter the major and restructuring our
in fourth constant grew of basis currency. more discuss quarter results or X.X% on million detail. X.X% our Now a let's reported Revenue in $XXX.X
of business in an percentages these from and true selling that you royalty extra offset growth period prior-year as remind $X.X revenue more Diagnostics, day. Blood understate than me our non-recurring million which divested our benefited sales from Molecular the Screening Let higher
sixth robust double-digit consecutive XX.X% geography, of legacy growth terms Cynosure. quarter, excluding franchises demonstrated our quarter our in of fourth International In growth the
Our broad-based which Surgical still that the Cynosure made and well we business total of solid franchises. fourth United the Molecular an were as X.X%. the million, Diagnostics, the period, nicely in Surgical reflecting have International contributed increase Diagnostics in declined internationally, improved had the States, in quarter in as sequentially Health positive of emerged a growth Breast OUS in quarter rates In improvements our products, sales Breast exceptional $XXX.X our and sales recent and business continued years. third Health, trends Including
in on detail our fourth let provide me Now results quarter. the divisional some more revenue
Our Breast different external Breast totaled an X.X%, position robust cyclical growth a defying as about Internationally, million, including in with and Global to the $XXX.X concerns sales $X than reemerged million driver about in year business, a we from sales well a Health, increase growth perform very largest important has decline. Faxitron. is a continue of clearly ago mid-teens. Health
couldn't and Interventional, Systems the strategic larger business revitalized growth breast posted helped globally new seven In and building be whole of for us as team market growth clinically core, proud only we ability X,XXX the clear the X.X%, cancers quarter the It's compared systems sustainable forecast. Cumulatively, slightly have Their and hardware. detect over continue reducing business continue growth cycles have success market increased service. while with XD our patients, share. the best XD base I'll States addition, in quarters, of validating our time, XXXX, and the strengthened systems growth customers, know nearly payers stronger-for-longer end more we a our the Since than the additional products year-end the shipped United the a four in quarter the boom-bust in year, to was working evident much We fiscal not recognize this quarter. of down to software are XDimensions but rate had fiscal of placements in sales our for was placements, unnecessary invasive X,XXX franchise, it's U.S. just as in introduction the Breast last in and to runway At gain more Performance of simultaneously diversified, again States the X.X% same differentiated to past. overcome our callbacks. this quarters. as we upgrade the to that by XD systems and broad-based, more new United that surgery you new of imaging product the encompassing At our mammography, let our to installed shipped still ahead of
financial competitor our which For domestic reinforce globally partner to in rapidly breast-conserving entry from showed X,XXX products overall, the example, XD challenges recurring to throughout BioZorb, biopsy XX.X% Breast breast we with three-dimensional about capital. cancer base, Sales units Interventional strengthens innovative of return treatment. nearly revenue of we invested XD XX% surgery also the closed acquiring To market here and point, Faxitron, and our through our installed have acquisition And care with broadens driven ability rate is in robust again, market in for Growth digits an including more reaching accretive that as marker recent and base margins, products implantable, also From a sales overcome increasing continuum an for that with still in is their we new a being penetrated the growth Focal the in XX% surgery. our by Focal's double force only but helps highlight provides in such field. portfolio gross to position called customers. XD quarter. penetrated the Combined our on estimate own clinicians wanted growth comprehensively main breast-conserving perspective, product about is is as and tuck-in means fourth Focal that units. important to an help screening early the breadth growing our this of leveraging our marker of our which system, October. Brevera expands by last of acquisition diagnosed our women whole is consecutive attractive Focal revenue
layering addition, much greater Focal Hologic's In help should and then capabilities going resources and accelerate Faxitron, growth forward. combining on
Breast been built new mammography based and never of a systems, core core, two today Our complementary it division Health is clinically-differentiated stronger on acquisitions. multiple tuck-in than this around products has
$XXX.X declined revenue Diagnostics, X.X%. where to turn let's of Now, million
As healthy items had quarter, Diagnostics number growth represent does the not affecting we discussed, business. this what's headline very a some unusual so actually
grew rate, the our the excluding assay and was And still roughly million year women's Molecular U.S., the from remain the virology non-recurring primary of Molecular But mid-single-digit $X.X grew a underlying revenue of digits growth system, Panther royalty from market-leading XX in shares in of on although royalty in market we a Aptima, already enjoy year drivers our sales Molecular Sales grew healthy million double ago. actually categories, prior XX.X%, health exclude assays business. quarters. quarter. X.X%. ninth key growth high Molecular the Internationally, for second accelerating in example, For if period, you revenue consecutive for in $XXX the time
more shipped around units, more world, Panthers outside more the lab than to to of XXXX, of total course XXX XX% States. Over our the more we customers now which than are the United cumulative than X,XXX bringing
these has Average customers on exceeds volume. we double-digit grew R&D now as overall revenue year partner in global utilization with drive a new rate and and Importantly, at a Panther pipeline basis instruments emerge from to grow low continued of as assays $XXX,XXX XXXX. testing our to fiscal per a
cancer high in and longer States, sales In market remains challenged of cytology cytology $XXX.X the quarter. on, perinatal growth intervals. fourth testing and United our X.X% to Moving cervical declined million the due shares
to see tests their because than States draft grade identifies data pre-cancers between or the and final the Both large reversed during issue testing cervical in test alone. the used quarter, Force earlier cervical for an However, retained pleased Preventive guidelines United either testing final that and XX we were Task HPV cancer an guidelines. women prove A crucial co-testing These cancers fourth from Pap are more ages Services + XX. multiple of co-testing studies and
business have in the final commonly cancer more cervical the for USPSTF remove is expected simple, an decline of million, States, United to XX.X% and believe the Blood Diagnostics, related revenue depressed investors, whole. approach recommendations that $XX.X we Diagnostics used rates concern division but near-term to our highly the and screening as continue method a divested importantly accurate our Screening totaled access women for Elsewhere in that to a company growth So will that an ensure most cost-effective.
concern about our Diagnostics business. move to wanted you a had of address we Before some we on,
with been our multi-year know that and solidify While a providing molecular in business outsized a to been weeks, of two And largest diligently these tests to to there I'm have continue contract, instrumentation customers. working actually to on you our we deal let has and customers. recent we've pleased signed one single cytology focus lab
on terms for have contract and customer contract extension we in other finalize our to few a multiyear expect addition, weeks. the this In supply with next agreed of the
incorporated have the years our the financial don't you contracts, are to I our of shared details look we with we to to with discuss outcome know, we individual both but tell importantly, customers that Most you for forward come. and businesses in pleased guidance. effects continuing work As XXXX this grow will to
Surgical division, let's our where Now sales million cover of GYN grew $XXX.X X.X%.
course our last each in improved growth the quarter fourth as XXXX, call. in to the Over predicted Surgical meaningful of and we steadily returned
have the modest compared recent mid-single but Surgical competitive than approach. become were MyoSure, discussed, the prior As to digits low-double and to down sales digits overall quarter. the improving we show line in Surgical less leadership sales team product quarter, performance, their our see franchise, culture to which improvement, year. trends of are has growing beginning largest declining sequential our the NovaSure aggressive benefits in force of of continued the strong the still new in continued the third we is more
Surgical, a our Apart ongoing royalty. should customers. to agreeing from the we Smith we weeks fourth that to from seeing patent these and recent & Fluent highlight related we Finally, Nephew dispute in MyoSure, also million early them in and $XX.X good in operational system fluid settled are long-standing a management pay results interest launched quarter with small
are to more can matter so us this pleased behind the put fully business. We on growing focus we
where sales to Now $XX.X million let's turn of Medical Aesthetics declined XX.X%.
to by Stanley suspend disclosed marketing and we Conference, women's TempSure affected of sales our procedures on in our voluntary Morgan Cynosure product. the were decision letter Vitalia certain negatively the FDA health September As before
probes, were lower Specifically, systems, expected been reflecting domestic coming market. Touch with to million more and rebates $XX in TempSure refunds to quarter as initially associated than with unused due sales well fourth and prior of as handpieces, the MonaLisa up sales would in-line than force for an is sales have reduced what remains attractive revenue in these Normalizing speed expectations, sales. a that growth Vitalia effects, roughly
more MonaLisa in labeling. our concerns to have specific hopefully We to FDA's collaboratively response the and indications with are lead clinical adjusted to marketing and messages Touch will the working trials for that design agency
higher Touch a on communicate we playing like products so field we discussion us testing more that which strong that tremendous the $XX.X MonaLisa million performance our revenue of provide. system To as continue continue management. and a of scrutiny time We we believe level to value density can sales over to regulatory will see level bone round benefit grew briefly, out the welcome Skeletal for of X.X% Horizon human sales
So, with nice largest strength good Breast posted tuck-in to and second in Surgical, our very a internationally. wrap acquisition We successes attractive in up, and Health. Health, results logged Molecular quarter and business, Breast with both financial continued we in USPSTF completed momentum some for improving the Diagnostics our the customers, and Diagnostics,
much when forward XXXX a we to than better trajectory growth began XXXX. We look exiting continued in are clearly and on year, we the
the I'll Now Karleen. to turn call over
